![](/img/cover-not-exists.png)
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q.M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke,Volume:
13
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.05.004
Date:
November, 2018
File:
PDF, 698 KB
english, 2018